Vietnam Investment Review on MSN
Daewoong lung drug sails past third safety review
"This third IDMC recommendation represents a major milestone reaffirming the safety and progress of Bersiporocin," said Seong ...
6d
JASCAYD® (nerandomilast) approved in China for the treatment of idiopathic pulmonary fibrosis (IPF)
Ingelheim, GermanyApproval is based on results from Phase III FIBRONEER™-IPF trial, which showed statistically significant improvements in the ...
The investigators hypothesized that AFM might be able to identify unique nanomechanical fingerprints (NMFs) in tissue samples ...
Researchers uncovered how lung cells decide whether to rebuild tissue or fight infection. This built-in “switch” may be the ...
More than 50% of lung-transplant recipients experience a rejection of their new lung within five years of receiving it, yet ...
Avalyn will present four posters in conjunction with the PFF Summit 2025 Welcome Reception from 5-8 p.m. CT on Thursday, November 13, 2025.
MedPage Today on MSN
Could This Be the First Disease-Modifying Drug in Bronchiectasis?
CHICAGO -- Brensocatib (Brinsupri) appeared to have a disease-modifying effect on structural lung changes in non-cystic ...
Data presented at the CHEST 2025 Annual Meeting highlight deupirfenidone’s differentiated profile and potential to address unmet needs across age groups PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ( ...
Finger clubbing, a change in nail shape and fingertip swelling, can be an early indicator of lung cancer, though it often ...
Boehringer Ingelheim’s Jascayd approved in China to treat idiopathic pulmonary fibrosis: Ingelheim, Germany Thursday, October 23, 2025, 12:00 Hrs [IST] Boehringer Ingelheim’s ...
Boehringer Ingelheim has announced that China's National Medical Products Administration (NMPA) has approved JASCAYD (nerandomilast) as an oral treatment option for idiopathic pulmonary ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback